European Journal of Immunology · 2019 · 60 citations · 36 references
Life SciencesCell BiologyImmunologyCellular MetabolismMitochondrial BiologyNeuroimmunologyGlycolysis RegulationImmune Cell MetabolismMitochondrial DysfunctionMitochondrial MetabolismMultiple SclerosisT Cell BiologyEffector Memory T CellsEffector T Cell MetabolismGlucose TransportMemory Effector T CellsMetabolic Rate ChangesMetabolic Regulation Of T Cell DifferentiationMultiple Sclerosis ImmunopathogenesisTh17 Cell Differentiation
Patients with primary progressive (PP) and secondary progressive (SP) forms of multiple sclerosis (MS) exhibit a sustained increase in the number of Th1, T cytotoxic type-1 and Th17 cells in peripheral blood, suggesting that the progressive phase is characterized by a permanent peripheral immune activation. As T cell functionality and activation are strictly connected to their metabolic profile, we investigated the mitochondrial functionality and metabolic changes of T cell subpopulations in a cohort of progressive MS patients. T cells from progressive patients were characterized by low proliferation and increase of terminally differentiated/exhausted cells. T cells from PP patients showed lower Oxygen Consumption Rate and Extracellular Acidification Rate, lower mitochondrial mass, membrane potential and respiration than those of SP patients, a downregulation of transcription factors supporting respiration and higher tendency to shift towards glycolysis upon stimulation. Furthermore, PP effector memory T cells were characterized by higher Glucose transporter -1 levels and a higher expression of glycolytic-supporting genes if compared to SP patients. Overall, our data suggest that profound differences exist in the phenotypic and metabolic features of T cells from PP and SP patients, even though the two clinical phenotypes are considered part of the same disease spectrum.
36
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Federica Sallusto, Danielle Lenig, Reinhold Förster et al. · Nature · 1999 · 5.8K citations
Defining the clinical course of multiple sclerosis
Fred Lublin, Stephen C. Reingold, Jeffrey A. Cohen et al. · Neurology · 2014 · 3.1K citations · Full text
Ryan D. Michalek, Valerie A. Gerriets, Sarah R. Jacobs et al. · The Journal of Immunology · 2011 · 2K citations · Full text
Inhibitory effect of tumor cell–derived lactic acid on human T cells
Karin Fischer, Petra Hoffmann, Simon Voelkl et al. · Blood · 2007 · 1.9K citations · Full text
Life Sciences, Immunology, Oncology +17